In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study

In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study

Abstract Background: Despite successful opening of culprit coronary artery, myocardial reperfusion does not always follows primary percutaneous coronary intervention (PPCI). Glycoprotein IIb/IIIa inhibitors are used in the treatment of no-reflow (NR), but their role to prevent it is unproven. Obje...

Full description

Bibliographic Details
Main Authors: Igor Matos Lago, Gustavo Caires Novaes, André Vannucchi Badran, Rafael Brolio Pavão, Ricardo Barbosa, Geraldo Luiz de Figueiredo, Moysés de Oliveira Lima Filho, Jorge Luiz Haddad, André Schmidt, José Antônio Marin Neto
Format: Article
Language:English
Published: Sociedade Brasileira de Cardiologia (SBC)
Series:Arquivos Brasileiros de Cardiologia
Subjects:
Doença Arterial Coronariana
Infarto do Miocárdio
Intervenção Coronária Percutânea
Complexo Glicoproteico CPIIb IIIa de Plaquetas
Angioplastia
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016004400403&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016004400403&lng=en&tlng=en

Similar Items